Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price traded up 2.9% on Monday . The company traded as high as $12.49 and last traded at $12.47. 95,243 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 383,352 shares. The stock had previously closed at $12.11.
Wall Street Analysts Forecast Growth
MESO has been the topic of several analyst reports. Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a report on Tuesday, March 4th. Jefferies Financial Group downgraded shares of Mesoblast from a "buy" rating to a "hold" rating in a research report on Monday, December 23rd. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $24.00 target price (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Mesoblast has a consensus rating of "Moderate Buy" and an average target price of $18.00.
Check Out Our Latest Report on MESO
Mesoblast Stock Performance
The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The firm has a 50-day moving average price of $16.09 and a 200 day moving average price of $13.29.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in shares of Mesoblast in the fourth quarter valued at about $30,000. Barclays PLC acquired a new position in shares of Mesoblast during the 4th quarter worth approximately $38,000. Lindbrook Capital LLC boosted its stake in shares of Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock valued at $43,000 after buying an additional 901 shares during the period. JPMorgan Chase & Co. bought a new position in Mesoblast during the 4th quarter worth $50,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Mesoblast by 86,566.7% during the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after purchasing an additional 2,597 shares in the last quarter. 1.43% of the stock is owned by institutional investors and hedge funds.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Read More
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
